• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Roche - Articles and news items

pharmacy-pills

Price discount helps give green light for Roche’s breast cancer drug

Industry news / 21 November 2016 / Niamh Louise Marriott, Digital Content Producer

A discount to the price of pertuzumab agreed with the company was an important factor in enabling NICE to overturn its earlier provisional decision…

globe-pill

GSK tops list ranking big pharma’s global access to medicine

Industry news / 14 November 2016 / Niamh Louise Marriott, Digital Content Producer

Read how the 2016 Access to Medicine Index ranks the top 20 pharmaceutical companies on their efforts to improve access to medicine in low- and middle-income countries…

parkinsons-disease

Prothena’s Phase 1b Parkinson’s disease study showed robust antibody CNS penetration

Industry news / 11 November 2016 / Niamh Louise Marriott, Digital Content Producer

Prothena’s Phase 1b multiple ascending dose study of PRX002 trial found an acceptable safety and tolerability profile in patients with Parkinson’s disease…

assay

FDA approves Roche’s immunotherapy assay to support treatment decisions in lung cancer

Industry news / 31 October 2016 / Niamh Louise Marriott, Digital Content Producer

The US Food and Drug Administration (FDA) has approved Roche’s PD-L1 assay as a diagnostic to identify PD-L1 expression levels in patients considering treatment with Tecentriq (atezolizumab) for previously treated metastatic non-small cell lung cancer (NSCLC). The PD-L1 (SP142) assay is also indicated to identify patients with urothelial cancer (UC) who may benefit from treatment […]

epr_ispe

FDA approves Roche’s blood screening assay for donor screening

Industry news / 24 October 2016 / Niamh Louise Marriott, Digital Content Producer

The cobas MPX assay enables donor screening laboratories to apply the most advanced PCR-based diagnostic technology to the surveillance of donated blood…

lymphoma

Roche’s ALK-positive NSCLC drug granted FDA breakthrough designation

Industry news / 4 October 2016 / Niamh Louise Marriott, Digital Content Producer

This second alecensa breakthrough therapy designation granted is based on phase 3 J-ALEX study, treat ALK-positive non-small cell lung cancer…

roche-skin-cancer-not-effective

NICE says Roche’s skin cancer drug not cost effective

Industry news / 6 September 2016 / Niamh Louise Marriott, Digital Content Producer

The committee agreed the combination offers life extending benefit compared to vemurafenib alone, however compared to alternative treatments it is too expensive. About 1,000 people would have been eligible each year…

study-roche

Roche’s cancer immunotherapy drug has longer OS vs. chemotherapy

Industry news / 1 September 2016 / Niamh Louise Marriott, Digital Content Producer

Roche’s study for tecentriq (atezolizumab) met its co-primary endpoints and showed a statistically significant and clinically meaningful improvement in overall survival (OS) compared with docetaxel chemotherapy in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on or after treatment with platinum-based chemotherapy. Adverse events were consistent with what has […]

Gazyvaro Roche

Blood cancer study yields disappointing results

Industry news / 19 July 2016 / Niamh Louise Marriott

Gazyvaro did not meet its primary endpoint of significantly reducing the risk of disease worsening or death in people with diffuse large B-cell lymphoma…

Ocrevus

Ocrevus marketing applications under review by the EMA and FDA

Industry news / 28 June 2016 / Victoria White, Digital Content Producer

If approved by the EMA and FDA for both indications, Ocrevus would be the first and only treatment for both forms of multiple sclerosis…

Takeda & Seattle Genetics announce positive data from trial for cutaneous T-cell lymphoma 

EC approves Gazyvaro plus bendamustine in follicular lymphoma

Industry news / 16 June 2016 / Victoria White, Digital Content Producer

The EC has approved Gazyvaro in combination with bendamustine chemotherapy followed by Gazyvaro maintenance in people with follicular lymphoma…

Tecentriq

Tecentriq to dominate the bladder cancer market, says GlobalData

Industry news / 14 June 2016 / Victoria White, Digital Content Producer

The launch of Roche’s Tecentriq will usher in a dramatic change in the treatment paradigm of bladder cancer, according to an analyst with GlobalData…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +